DRIVE-SHIFT Study: Switch to DOR/3TC/TDF in HIV Patients - Efficacy and Drug Resistance Analysis
The DRIVE-SHIFT study evaluated switching to DOR/3TC/TDF in HIV patients with suppressed viral loads. The study aimed to assess the efficacy of DOR/3TC/TDF compared to continuation of current antiretroviral therapy (cART) at both 24 and 48 weeks. Results showed non-inferiority of DOR/3TC/TDF in main
1 views • 7 slides
Study of Maraviroc-Containing Regimens for HIV PrEP in U.S. Women: HPTN 069/ACTG A5305 Phase II Study
HPTN 069/ACTG A5305 is a Phase II study evaluating the safety and tolerability of Maraviroc (MVC)-containing regimens compared to Tenofovir/emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP) in at-risk women. The study involves a randomized, double-blind, placebo-controlled design with
0 views • 18 slides
Comparing TDF-FTC vs Placebo as HIV PrEP for Transgender Women in iPrEx Trial Substudy
Subgroup analysis from the iPrEx trial and open-label extension assessed the efficacy, drug concentrations, and adherence of TDF-FTC PrEP for transgender women assigned male at birth. Results indicate varying drug detection consistency and non-condom receptive anal intercourse among participants.
1 views • 7 slides
Comparison of NNRTI vs. NNRTI and RPV/FTC/TDF vs. EFV/FTC/TDF in STAR Study
STAR Study compared the efficacy and safety of RPV/FTC/TDF and EFV/FTC/TDF in treatment-naive HIV patients. The study included 394 participants in each group, assessing HIV RNA suppression rates, CD4 count improvements, treatment responses, and resistance analyses up to 48 weeks. Results showed RPV/
0 views • 15 slides
Comparison of INSTI vs. EFV in STARTMRK GS-US-236-0102
In the STARTMRK study, Raltegravir (RAL) was compared to Efavirenz (EFV) in combination with TDF/FTC for the treatment of HIV. The study aimed to demonstrate non-inferiority of RAL compared to EFV in achieving HIV RNA levels below 50 c/mL. Baseline characteristics and patient disposition were assess
0 views • 12 slides
Impact of Antiretroviral Treatment on Weight and Obesity in HIV Patients
Dolutegravir (DTG) treatment has shown associations with weight gain and clinical obesity, particularly in black individuals and women. In contrast, tenofovir disoproxil fumarate (TDF) is linked to lower body weight compared to other treatments. Trials like ADVANCE and NAMSAL have provided insights
0 views • 31 slides
Comparing Efficacy of LPV/r QD vs. BID in Combination Therapy
Study M02-418 compared once-daily (QD) and twice-daily (BID) LPV/r in combination with TDF and FTC for HIV treatment. The primary endpoint was achieving HIV RNA <50 c/mL at week 48, aiming for non-inferiority of QD vs. BID dosing. Patient characteristics, treatment response at week 48, and pharmacok
0 views • 7 slides
Comparison of NNRTI vs NNRTI and DRIVE-AHEAD Study: DOR/3TC/TDF vs EFV/FTC/TDF
The comparison study explores NNRTI regimens alongside the DRIVE-AHEAD trial, focusing on DOR/3TC/TDF vs EFV-FTC/TDF. DRIVE-AHEAD assesses the efficacy and safety of DOR in ARV-naïve HIV patients, aiming for non-inferiority based on virologic response, with DOR exhibiting potential neuropsychiatric
0 views • 11 slides
F/TAF vs. F/TDF for HIV Pre-Exposure Prophylaxis: DISCOVER Study Findings
Study results reveal that F/TAF provides rapid onset and longer sustained HIV protection compared to F/TDF in pre-exposure prophylaxis. The randomized noninferiority trial included 2694 participants with a primary analysis at weeks 48 and 96. Disclosure statements indicate involvement of various hea
0 views • 21 slides